UK markets closed

KROS Sep 2024 75.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.39000.0000 (0.00%)
As of 11:01AM EDT. Market open.
Full screen
Previous close4.3900
Open4.3900
Bid0.0000
Ask5.0000
Strike75.00
Expiry date2024-09-20
Day's range4.3900 - 4.3900
Contract rangeN/A
Volume1
Open interestN/A
  • GlobeNewswire

    Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

    LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8

  • GlobeNewswire

    Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

    LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat prese

  • GlobeNewswire

    Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

    LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. “On behal